Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant Augmentation in MDD with Residual Insomnia
NCT02669030Phase 4Terminated
- Sponsor
- Institute for Advanced Medical Research
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of suvorexant in major depressive disorder (MDD), Insomnia, sponsored by Institute for Advanced Medical Research. Started Mar 2017; status: terminated.
02
Drugs
suvorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT02669030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669030.